Kojiro Tashiro
Overview
Explore the profile of Kojiro Tashiro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
66
Citations
166
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tiwari A, Paithane U, Friedlein J, Tashiro K, Saulnier O, Barbosa K, et al.
bioRxiv
. 2025 Mar;
PMID: 40027648
MYC-driven (MYC+) cancers are aggressive and often fatal. MYC dysregulation is a key event in these cancers, but overexpression of MYC alone is not always enough to cause cancer. (),...
2.
Urabe F, Tashiro K, Muramoto K, Yanagisawa T, Katsumi K, Takahashi H, et al.
Urol Oncol
. 2025 Mar;
PMID: 40023743
Background: Androgen receptor-signaling inhibitors (ARSIs) have significantly changed the preferred treatments for metastatic castration-sensitive prostate cancer (mCSPC). Despite such advances, the prognostic significance of metastases at specific sites remains unclear....
3.
Shibata K, Iwatani K, Imai Y, Yoshihara K, Miyajima K, Fukuokaya W, et al.
In Vivo
. 2025 Feb;
39(2):824-833.
PMID: 40010955
Background/aim: The lung immune prognostic index (LIPI), which is determined by assessing the derived neutrophil-to-lymphocyte ratio in conjunction with the level of lactate dehydrogenase, predicts outcomes in various cancers. Its...
4.
Yamada H, Tashiro K, Takahashi Y, Honda M, Ohnuma H, Yasue K, et al.
J Infect Chemother
. 2025 Feb;
31(4):102645.
PMID: 39921090
The purpose of this study was to investigate whether conventional levofloxacin (LVFX) administration is unnecessary for transrectal ultrasound-guided prostate needle biopsy (TRP-Bx) in view of the increase in LVFX-resistant Escherichia...
5.
Urabe F, Kadena S, Tashiro K, Tokuoka K, Taneda Y, Fujiwara K, et al.
Jpn J Clin Oncol
. 2025 Jan;
PMID: 39820640
Background: Despite its demonstrated efficacy in prolonging overall survival (OS) and delaying skeletal-related events in the ALSYMPCA trial, the optimal timing of radium-223 initiation remains unclear. This study investigated factors...
6.
Taneda Y, Urabe F, Uchida N, Kadena S, Shibata K, Hashimoto M, et al.
Jpn J Clin Oncol
. 2025 Jan;
PMID: 39820356
Background: The JAVELIN Bladder 100 trial demonstrated improved overall survival (OS) with maintenance avelumab in patients with locally advanced or metastatic urothelial carcinoma UC (la/mUC) who achieved disease control following...
7.
Yamaguchi R, Kagawa H, Yoshihara K, Yamamoto S, Hara S, Miyajima K, et al.
Transl Androl Urol
. 2024 Dec;
13(11):2384-2395.
PMID: 39698572
Background: Despite the availability of advanced imaging technologies, it remains difficult to achieve sufficient staging accuracy to ensure a tailored treatment strategy for patients with upper tract urothelial carcinoma (UTUC)....
8.
Imai Y, Urabe F, Sadakane I, Oguchi T, Iwatani K, Murakami M, et al.
Transl Androl Urol
. 2024 Oct;
13(9):2027-2035.
PMID: 39434761
Background: Multiparametric magnetic resonance imaging (mpMRI) is increasingly used for the early detection of clinically significant prostate cancer (csPCa). However, the achievement of accurate detection rates, particularly for transition zone...
9.
Hara S, Urabe F, Tashiro K, Goto Y, Iwamoto Y, Ohtsuka T, et al.
Jpn J Clin Oncol
. 2024 Oct;
55(2):158-163.
PMID: 39426804
Objective: We determined the optimal timing for initiating androgen receptor signaling inhibitor (ARSI) therapy in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and assessed its impact on oncological outcomes. Materials...
10.
Yanagisawa T, Fukuokaya W, Hatakeyama S, Narita S, Muramoto K, Katsumi K, et al.
Prostate
. 2024 Oct;
85(2):165-174.
PMID: 39417629
Purpose: We aimed to assess the differential efficacy and safety of androgen receptor pathway inhibitors (ARPI), such as abiraterone, enzalutamide, and apalutamide, in patients with metastatic hormone-sensitive prostate cancer (mHSPC)...